Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Vivani Medical, Inc. - SIC # 3840 -
Ticker
Exchange
SIC #
Website
Latest Ticker
VANI
Nasdaq
3840
www.vivani.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Vivani Medical, Inc.
Vivani Medical Announces Positive Top-Line Results from SLIM-1™, a First in Human Phase 1 Trial of NPM-139 (semaglutide implant) and Wegovy (weekly semaglutide injections) in Obese and Overweight Subjects
- Nov 12th, 2026 6:00 am
Vivani Medical: Q3 Earnings Snapshot
- Nov 11th, 2026 2:20 pm
Vivani Medical Reports Third Quarter 2026 Financial Results and Provides Business Update
- Nov 11th, 2026 2:05 pm
Vivani Medical Announces Participation in Upcoming Investor Conferences
- Oct 12th, 2026 5:00 am
Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly?
- Aug 29th, 2026 5:35 pm
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
- Aug 13th, 2026 2:05 pm
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
- Aug 6th, 2026 6:00 am
Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal
- Jul 15th, 2026 5:02 pm
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026
- Jul 14th, 2026 2:03 pm
Presenting on Emerging Growth Conference 94 Day 1 on July 15; Register to live stream
- Jul 14th, 2026 5:00 am
Novo Nordisk (CPSE:NOVO B) Could Be 13% Overvalued Following Its Vivani Deal
- Jul 9th, 2026 10:12 am
Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant
- Jul 8th, 2026 5:11 am
Novo Nordisk (CPSE:NOVO B) Teams Up With Vivani To Test A Semaglutide Implant
- Jul 7th, 2026 1:18 pm
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
- Jul 7th, 2026 5:35 am
Vivani strikes reverse-merger agreement with ClearOne for BCI business
- Jul 3rd, 2026 5:40 am
Why Did CLRO Stock Surge More Than 170% Today?
- Jul 2nd, 2026 11:53 am
Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.
- Jul 2nd, 2026 6:00 am
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker
- Jun 26th, 2026 5:30 am
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
- Jun 25th, 2026 5:30 am
Scroll